Payment overview · 2025
General Payments
$224.05
2 reported records · 2 companies
Healthcare provider profile · identity verified
Heidi Braunschweig, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · SIOUX CITY, IA · NPI 1720569007
Verified facts
What the public records show
CMS Open Payments records show Heidi Braunschweig, ARNP received $224.05 in general payments during 2025 across 2 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 55.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 210 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $125.00 | 55.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $99.05 | 44.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $224.05 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $99.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
210 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 543 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 459 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 448 | 46 |
| Gabapentin | Gabapentin | 345 | 32 |
| Bumetanide | Bumetanide | 299 | 22 |
| Amlodipine Besylate | Amlodipine Besylate | 296 | 30 |
| Trazodone Hcl | Trazodone Hcl | 288 | 31 |
| Potassium Chloride | Potassium Chloride | 269 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 254 | 27 |
| Allopurinol | Allopurinol | 253 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 235 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 221 | 22 |
| Eliquis | Apixaban | 210 | 17 |
| Lisinopril | Lisinopril | 203 | 22 |
| Furosemide | Furosemide | 191 | 25 |
| Omeprazole | Omeprazole | 155 | 18 |
| Sertraline Hcl | Sertraline Hcl | 149 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 143 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 116 | 13 |
| Trulicity | Dulaglutide | 116 | 15 |
| Mirabegron Er | Mirabegron | 115 | 20 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 112 | 14 |
| Metformin Hcl Er | Metformin Hcl | 111 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 107 | suppressed |
| Aripiprazole | Aripiprazole | 106 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 105 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 104 | 22 |
| Pregabalin | Pregabalin | 104 | 13 |
| Insulin Aspart Flexpen | Insulin Aspart | 101 | 15 |
| Losartan Potassium | Losartan Potassium | 92 | suppressed |
| Glipizide Er | Glipizide | 91 | suppressed |
| Risperidone | Risperidone | 88 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 88 | 19 |
| Myrbetriq | Mirabegron | 82 | 17 |
| Carvedilol | Carvedilol | 81 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 81 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 80 | suppressed |
| Prednisone | Prednisone | 80 | 19 |
| Spironolactone | Spironolactone | 80 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 71 | 35 |
| Calcitriol | Calcitriol | 69 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 68 | suppressed |
| Finasteride | Finasteride | 67 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 64 | suppressed |
| Digoxin | Digoxin | 57 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | suppressed |
| Irbesartan | Irbesartan | 54 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 54 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | suppressed |
| Lamotrigine | Lamotrigine | 52 | suppressed |
| Mirtazapine | Mirtazapine | 52 | suppressed |
| Clonazepam | Clonazepam | 51 | suppressed |
| Gemtesa | Vibegron | 51 | suppressed |
| Metformin Hcl | Metformin Hcl | 50 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 50 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 49 | suppressed |
| Memantine Hcl | Memantine Hcl | 49 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 48 | suppressed |
| Tradjenta | Linagliptin | 48 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | suppressed |
| Famotidine | Famotidine | 45 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 43 | suppressed |
| Cephalexin | Cephalexin | 39 | 21 |
| Primidone | Primidone | 39 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 38 | suppressed |
| Cholestyramine Light | Cholestyramine | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Simvastatin | Simvastatin | 34 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 24 |
| Lorazepam | Lorazepam | 33 | 11 |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 30 | suppressed |
| Loperamide | Loperamide Hcl | 30 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Olanzapine | Olanzapine | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Acetazolamide | Acetazolamide | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 18 |
| Carvedilol Er | Carvedilol Phosphate | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 12 |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 21 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Roflumilast | Roflumilast | 20 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 20 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 19 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 19 | 15 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 18 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 18 | suppressed |
| Acamprosate Calcium | Acamprosate Calcium | 17 | suppressed |
| Acetylcysteine | Acetylcysteine | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Rexulti | Brexpiprazole | 17 | suppressed |
| Safetyglide Insulin Syringe | Syringe,needle,insuln,safe,1ml | 17 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 16 | 16 |
| Atenolol | Atenolol | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 16 | suppressed |
| Insulin Aspart | Insulin Aspart | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Prolia | Denosumab | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Ulticare Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 12 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Droxidopa | Droxidopa | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $224.05 · 2 records | Teva Pharmaceuticals USA, Inc. | AUSTEDO XR, COBENFY | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error